Pharma giant Jazz dismisses final patent claim involving cannabinoid epilepsy drug
Global pharma company Jazz Pharmaceuticals has ended patent claims related to its cannabinoid-based epilepsy drug, Epidiolex.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
